Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958669 | 0.97 | MAPT (0.61) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| SCHEMBL9958513 | 0.86 | NOTUM (0.52) | MAPTLMNANOTUMKIF11QDPR | |
| Water SCHEMBL28315294 | 0.84 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| Water SCHEMBL9128367 | 0.84 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| Water SCHEMBL1648462 | 0.84 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| Water SCHEMBL11112402 | 0.84 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| SCHEMBL9958487 | 0.83 | NOTUM (0.48) | MAPTLMNANOTUMSMN1; SMN2TP53 | |
| SCHEMBL196583 | 0.80 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL9728 | 0.80 | MAPT (1.00) | MAPTLMNANOTUMKIF11SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3930145 | 0.77 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307595-A | Photosensitive dye/catalyst assembled electrode and preparation method and application thereof | 大连理工大学 | 2024-07-09 | — | — | CN | claimed |
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-115010653-A | Metal double terpyridyl ligand, ruthenium-containing supramolecular compound, and preparation method and application thereof | 江苏师范大学 | 2022-09-06 | — | — | CN | claimed |
| CN-114516809-A | AIE fluorescent probe based on dibenzylidene acetone and preparation method and application thereof | 西华师范大学 | 2022-05-20 | — | — | CN | claimed |
| CN-114478221-A | Pyrene-based AIE fluorescent probe and preparation method and application thereof | 西华师范大学 | 2022-05-13 | — | — | CN | claimed |
| CN-113880818-A | Organic compound and blue light organic electroluminescent device | 机光科技股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-1373755-A | Azacycloalkanone serine protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-10-09 | — | — | CN | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0944587-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2002-03-20 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-6022873-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-02-08 | — | — | US | claimed |
| EP-0944587-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| EP-0934292-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-11 | — | — | EP | claimed |
| US-5840974-A | Metalloproteinase inhibitors | BRITISCH BIOTECH PHARMACEUTICALS, LTD. (GB) | 1998-11-24 | — | — | US | claimed |
| WO-1998024759-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-11 | — | — | WO | claimed |
| WO-1998017655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-04-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | MAPT 3454/4885LMNA 1377/4885NOTUM 233/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | MAPT 3525/4885LMNA 1281/4885NOTUM 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.